

October 5, 2024

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

To

The Corporate Relations Department

BSE LIMITED

Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001

Company Code No. 524804

Company Code No. AUROPHARMA

Dear Sir/Madam,

Sub: Disposal of entire 24.5% shares held in Novagen BBBEE Invest Co (Proprietary) Limited, Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd.

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, we hereby inform you that Aurogen South Africa (Pty) Ltd., (Aurogen) a wholly owned step-down subsidiary of the Company in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary) Limited.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023, is enclosed as "**Annexure**".

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Encl.: Annexure

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.



Annexure

Annexure					
Sl No.	Particulars	Description			
a)	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary	Aurogen share in Novagen BBBEE Invest Co (Pty) Ltd	ZAR in million	INR in million	% of listed entity during last financial year
	or associate company of the listed entity during the last financial year(s);	Revenue	1.6	7.2	0.00%
		Net worth	0.1	0.5	0.00%
b)	date on which the agreement for sale has been entered into;	October 4, 2024			
c)	the expected date of completion of sale/disposal;	October 4, 2024			
d)	consideration received from such sale/disposal;	ZAR 245 (INR 1200)			
e)	brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Novagen BBEEE Invest Co. (Pty) Ltd is joint venture of step-down subsidiary, Aurogen. Aurogen owns 24.5% share, Clinigen SA Pty Ltd owns 24.5% and Rene Glyne Family Trust 51%. Buyer, Rene Glyne Family Trust, is an inter vivos trust registered under the laws of republic of South Africa. Rene Glyne Family Trust, the buyer, does not belong to the promoter/ promoter group/group companies of the Company.			
f)	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	The transaction would not fall within related party transactions.			
g)	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	or substantially the whole of the undertaking.			
h)	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable.			

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.